Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 4/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 2/20 | 1.00 |
| ▸ | F10 | P00742 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL29741503 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL22974994 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL18895186 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4375 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL15019460 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL20567702 | 1.00 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29618936 | 0.99 | F2 (0.99) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL20787652 | 0.99 | F2 (0.99) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL24209448 | 0.95 | F2 (0.90) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL28440979 | 0.90 | F2 (0.84) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2025-03-06 | — | — | US | disclosed |
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2024-10-24 | — | — | US | disclosed |
| EP-4380685-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4380603-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118022069-A | Tissue engineering tubular stent and preparation method and application thereof | 柔脉医疗(深圳)有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115703818-A | Separation method of argatroban 21 (R) and 21 (S) diastereoisomers | 康普药业股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023015230-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014354-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| EP-3797767-A1 | LEVOSIMENDAN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Pharnext (FR) | 2021-03-31 | — | — | EP | disclosed |
| CN-1668283-A | Pharmaceutical composition with improved dissolution | TRANSFORM PHARMACEUTICALS INC (US) | 2005-09-14 | — | — | CN | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004026235-A2 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | PCSK9, APOB, PCSK7 | F2 880/4885PRSS1 1129/4885F10 2186/4885 |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | F2 270/4885PRSS1 770/4885F10 49/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | F2 314/4885PRSS1 398/4885F10 613/4885 |
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | SERPINC1, SELP, ADAMTS13 | F2 5/4885PRSS1 640/4885F10 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.